Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2025 Results: November 7, 2024
Haemonetics Co. (NYSE: HAE) had its "outperform" rating re-affirmed by analysts at Barrington Research. They now have a $108.00 price target on the stock.
Is Haemonetics Corporation (HAE) an Undervalued Healthcare Stock to Buy in 2025 [Yahoo! Finance]
Haemonetics Co. (NYSE: HAE) is now covered by analysts at CL King. They set a "buy" rating and a $116.00 price target on the stock.
Haemonetics Co. (NYSE: HAE) is now covered by analysts at Bank of America Co.. They set a "neutral" rating and a $85.00 price target on the stock.